Navigation Links
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting

rsity of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA-based immunotherapies in Phase I clinical studies. The SECTA therapy for locally treating solid tumors is designed to selectively kill cancerous cells and minimize cosmetic or functional detriments often caused by surgical removal of predominantly healthy tissue typically treated around a tumor. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators , including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other signif
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research ... announced the addition of the "Investment Analysis ... report to their offering. ... investments in the US medical device sector identifies ... equity and venture capital investments, and mergers and ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... following open letter to shareholders from President & ... Dear RXi Shareholders, In ... statements posted on certain social media sites seem ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... , June 21 Ethicon Endo-Surgery, Inc. ... line of surgical devices, the HARMONIC ACE® 45 cm ... the reach of surgeons for minimally invasive procedures involving ... the standard length HARMONIC ACE® device. The additional length ...
... 21 Pfizer Inc. (NYSE: PFE ) announced today ... it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) ... the United States and that it will be voluntarily withdrawing the ... , , , ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive ... and marketing of a series of induction heating equipment. ... series of induction brazing equipments . , According ... brazing refers to the joining of two or ... The manager says that there are fundamental differences in ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Mass. - In a paper that suggests a new strategy ... colleagues report that the influenza virus infection in young mice ... asthma. The same protective effect was achieved by treating young ... ( H. pylori ), a bacterium that colonizes the ...
... 13 (HealthDay News) -- Exposure to a mineral found on ... of a type of lung cancer called mesothelioma, says a ... ash that has been altered by weathering and ground water, ... formations. It looks like transparent, glass-like fibers. Erionite has similar ...
... is available in French . Montreal, December ... significance has become loaded in our society, according to Anthony ... and Anthropology. In his most recent book, Re-Thinking Men: Heroes, ... men are to assume in society. Synnott spent ...
... HealthDay Reporter , FRIDAY, Dec. 10 (HealthDay News) ... type of breast cancer could potentially usher the majority ... breast cancer meeting said Friday. Presenting results from ... Symposium, scientists explained that administering two or more drugs ...
... frustrated by the lack of a meaningful way to screen ... that often progresses with few symptoms until it is too ... most commonly used biomarker used in screening, CA125, are also ... Duke Cancer Institute say that incorporating the latest information about ...
... higher prescription co-payment, especially among older women, is ... adjuvant aromatase inhibitor therapy, a life-saving therapy for women ... Dawn L. Hershman, MD, associate professor of medicine and ... the Herbert Irving Comprehensive Cancer Center at Columbia University, ...
Cached Medicine News:Health News:Study shows how flu infections may prevent asthma 2Health News:Study shows how flu infections may prevent asthma 3Health News:Road Material in N. Dakota May Up Lung Cancer Risk: Study 2Health News:This is a man's world? Yes and no, says new book 2Health News:Certain Drug Combinations May Beat Back Aggressive Breast Cancer 2Health News:Certain Drug Combinations May Beat Back Aggressive Breast Cancer 3Health News:Biological diversity of ovarian cancer lessens value of screening 2Health News:Higher co-payments increase chance of early discontinuation of breast cancer therapy 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: